TNFRSF17 and AL amyloidosis: The efficacy and safety of Ide-cel (bb2121) in patients with relapsed and refractory multiple myeloma and in subjects with high-risk multiple myeloma (KarMMA Phase II study) also reported the results of Ide-cel, another CAR-T therapy targeting BCMA.